Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 168

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 168
---
-L across other AML subtypes, we evaluated a panel of primary
bone marrow samples and peripheral blood from AML patients. We screened a preliminary panel of primary, treatment-naïve or on-therapy
AML bone marrow and PBMC samples by flow cytometry: (n=5 adverse, n=5 intermediate, n=1 APL, n=1 familial, n=5 N/A) (Table 1). We observed
both high percent (35.5 % ± 21.6) and geometric mean fluorescence index (“gMFI”) of cell surface TIM-4-L on a range
of AML bone marrow samples. The median gMFI of tertiles 1-3 was: T1 n=7, gMFI = 5033; T2 n=8, gMFI = 1873; T3 n=8, gMFI = 611. Of
note, the two on-therapy samples showed high percent and gMFI of cell surface TIM-4-L, with a patient receiving 5-azacytidine showing
1.8 fold TIM-4-L gMFI over median. The second patient receiving TKI therapy showed 3.3 fold TIM-4-L gMFI over median. Healthy donor samples
had much lower cell surface TIM-4-L, with a mean gMFI of 582. Circulating AML leukemic blasts were also evaluated for cell surface TIM-4-L
and showed high concordance with BM blasts, with high levels of cell surface TIM-4-L compared to healthy donor peripheral blood mononuclear
cells (“PBMCs”).

<div align='center'>96

Table 1. AML patient characteristics</div>

| Patient:   
 Patient ID |     | Treatment Status: Disease Status |     | Previous Treatments  |     | Patient Age At Collection |     | Gender |     | Race  |     | Patient:        
 Ethnicity       |     | % Blast Cells |     | Risk Category |     | Genetic Abnormality  |     | Cytogenetics |
| 200001107  |     | Newly Diagnosed                  |     | none                 |     |                        67 |     | Female |     | White |     | Non-            
 Hispanic/Latino |     |            91 |     | Adverse       |     | RUNX1                |     | N/A          |
| 200015767  |     | Newly